Document is current
Any future updates will be listed below
-
Authors
Panayi, Antonia http://orcid.org/0000-0002-1997-3705
Ward, Katherine
Benhadji-Schaff, Amir
Ibanez-Lopez, A Santiago http://orcid.org/0000-0003-4199-7911
Xia, Andrew http://orcid.org/0000-0002-4965-6807
Barzilay, Regina
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals International
- License Information
-
More Information
Article History
Received: 8 March 2023
Accepted: 13 September 2023
First Online: 6 October 2023
Declarations
:
: Not applicable.
: Not applicable.
: All authors have completed the ICMJE uniform disclosure form at ExternalRef removed and declare the following competing interests. AP and AB-S are employees of Takeda, and report holding stock and stock options in this company. KW is an employee of Oxford PharmaGenesis, which contributed to the conduct of the study with funding from Takeda and provided medical writing support, also funded by Takeda. ASI-L reports no competing interest. AX is a contractor of Takeda. RB received funding from Takeda to conduct this study.
